Program
Donepezil
Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.
Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 391 open or running | phase 4since Sep 12, 2005 | Nov 9, 2004 | May 6, 2030phase 1 · NCT07768592 |
| Pfizer | 70 open or running | phase 4since Sep 9, 2005 | Sep 8, 2005 | none ahead |
| Corium | 60 open or running | phase 1since Nov 13, 2016 | Nov 13, 2016 | none ahead |
| Merck | 50 open or running | phase 2since Feb 14, 2014 | Oct 21, 2008 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 1since Jan 3, 2012 | Jan 3, 2012 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Dec 14, 2010 | Dec 14, 2010 | none ahead |
| AstraZeneca | 30 open or running | phase 1since Jul 9, 2008 | Jul 9, 2008 | none ahead |
| Icure Pharmaceutical | 30 open or running | phase 3since Jun 22, 2017 | May 15, 2013 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 2since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | phase 1since Jan 11, 2011 | Jan 11, 2011 | none ahead |
| AbbVie | 10 open or running | phase 2since Aug 27, 2015 | Aug 27, 2015 | none ahead |
| dongkook-pharmaceutical-co-ltd | 10 open or running | phase 1since Feb 18, 2016 | Feb 18, 2016 | none ahead |
| teikoku-pharma-usa-inc | 10 open or running | phase 2since Jun 5, 2009 | Jun 5, 2009 | none ahead |
| theranexus | 10 open or running | phase 1since Oct 2, 2018 | Oct 2, 2018 | none ahead |
Also a collaborator on its studies: pt-equilab-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 29, 2007.
- Aug 27, 2015AbbVie's first study: phase 2 study in Dementia of Alzheimer's TypeNew to AbbVieAbbVie · NCT02549196 · 28 enrolled · United States
- Jan 18, 2016Phase 4 study in Dementia Associated With Cerebrovascular DiseaseEisai · NCT02660983 · 302 enrolled · Korea, Republic of
- Feb 18, 2016dongkook-pharmaceutical-co-ltd's first study: phase 1 study in Alzheimer DiseaseNew to dongkook-pharmaceutical-co-ltddongkook-pharmaceutical-co-ltd · NCT02695004 · 44 enrolled · Korea, Republic of
- Nov 13, 2016Corium's first study: phase 1 study in Alzheimer DiseaseNew to CoriumCorium · NCT02968719 · 107 enrolled · United States
- Jun 22, 2017Phase 3 study in Alzheimer DiseaseIcure Pharmaceutical · NCT03197740 · 399 enrolled · Korea, Republic of
- Aug 21, 2017Phase 1 study in Alzheimer DiseaseCorium · NCT03259958 · 86 enrolled · United States
- Nov 3, 2017Phase 1 study in Skin IrritationCorium · NCT03397862 · 256 enrolled · United States
- Jan 31, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03432195 · 66 enrolled · United States
- Feb 13, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03438604 · 24 enrolled · United States
- Oct 2, 2018theranexus's first study: phase 1 study in Cognitive DysfunctionNew to theranexustheranexus · NCT03698695 · 152 enrolled · France
- Mar 11, 2020Phase 1 study in Alzheimer DiseaseMerck · NCT04308304 · 27 enrolled · United States
- Nov 1, 2020Phase 1 study in Healthy SubjectsCorium · NCT04617782 · 60 enrolled · United States
- Jan 26, 2021Phase 1 study in Alzheimer DiseaseMerck · NCT04730635 · 44 enrolled · United States, Australia
- Aug 12, 2026Phase 1 study in Alzheimer DiseaseEisai · NCT07768592 · 32 planned
Ahead
- May 6, 2030Primary completion: phase 1 study in Alzheimer DiseaseEisai · NCT07768592
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768592Alzheimer Disease | 1 | Not yet recruiting | Eisai | May 6, 2030 | 32 |
| NCT04730635Alzheimer Disease · United States, Australia | 1 | Completed | Merck | Jan 20, 2023 | 44 |
| NCT04617782Healthy Subjects · United States | 1 | Completed | Corium | Apr 5, 2021 | 60 |
| NCT04308304Alzheimer Disease · United States | 1 | Completed | Merck | May 18, 2022 | 27 |
| NCT03698695Cognitive Dysfunction · France | 1 | Completed | theranexus | Oct 20, 2019 | 152 |
| NCT03438604Alzheimer Disease · United States | 1 | Completed | Corium | Jun 19, 2018 | 24 |
| NCT03432195Alzheimer Disease · United States | 1 | Completed | Corium | Jun 28, 2018 | 66 |
| NCT03397862Skin Irritation · United States | 1 | Completed | Corium | Mar 8, 2018 | 256 |
| NCT03259958Alzheimer Disease · United States | 1 | Completed | Corium | Mar 13, 2018 | 86 |
| NCT03197740Alzheimer Disease · Korea, Republic of | 3 | Completed | Icure Pharmaceutical | Jul 3, 2020 | 399 |
| NCT02968719Alzheimer Disease · United States | 1 | Completed | Corium | Jul 11, 2017 | 107 |
| NCT02695004Alzheimer Disease · Korea, Republic of | 1 | Completed | dongkook-pharmaceutical-co-ltd | Mar 2017 | 44 |
| NCT02660983Dementia Associated With Cerebrovascular Disease · Korea, Republic of | 4 | Completed | Eisai | Jul 13, 2018 | 302 |
| NCT02549196Dementia of Alzheimer's Type · United States | 2 | Completed | AbbVie | Sep 28, 2017 | 28 |
| NCT02345213Lewy Body Disease · Japan | 4 | Completed | Eisai | May 15, 2017 | 160 |
| NCT02178124Alzheimer Disease · Korea, Republic of | 1 | Completed | Icure Pharmaceutical | Dec 2014 | 24 |
| NCT02097056Alzheimer Disease · Korea, Republic of | 4 | Completed | Eisai | May 2015 | 171 |
| NCT02094053Down Syndrome · Japan | 2 | Completed | Eisai | Sep 16, 2016 | 36 |
| NCT02064920Alzheimer Disease | 2 | Completed | Merck | Jul 13, 2016 | 36 |
| NCT02051335Memory Disorders · United Kingdom | 1 | Completed | AstraZeneca | May 2014 | 27 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01923558Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2010 | 76 |
| NCT01923259Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2010 | 94 |
| NCT01860625Alzheimer Disease · Korea, Republic of | 1 | Completed | Icure Pharmaceutical | Dec 2013 | 36 |
| NCT01843556Healthy Elderly Male · Japan | 1 | Completed | Eisai | Apr 2013 | 48 |
| NCT01539031Alzheimer Disease · Japan | 3 | Completed | Eisai | Jan 2015 | 351 |
| NCT01506752Healthy Adult · Japan | 1 | Completed | Eisai | Sep 2011 | 20 |
| NCT01506739Healthy Adult · Japan | 1 | Completed | Eisai | May 2011 | 12 |
| NCT01504516Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2009 | 25 |
| NCT01504503Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2009 | 26 |
| NCT01485185Neuralgia · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 3, 2012 | 48 |
| NCT01439243Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2007 | 26 |
| NCT01439230Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Aug 2007 | 36 |
| NCT01404169Alzheimer Disease · China | 3 | Completed | Eisai | Jul 2014 | 260 |
| NCT01278407Lewy Body Disease · Japan | 3 | Completed | Eisai | Mar 2013 | 142 |
| NCT01276353Alzheimer Disease · Japan | 2 | Completed | Eisai | Apr 2012 | 45 |
| NCT01276080Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Nov 2009 | 36 |
| NCT01276067Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Nov 2009 | 32 |
| NCT01260948Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | May 2006 | 26 |
| NCT01260922Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | May 2006 | 26 |
| NCT01181310Dementia | 1 | Completed | Merck | Oct 2007 | 31 |
| NCT01082965Alzheimer Disease · United States | – | Terminated | Pfizer | Jul 2012 | 18 |
| NCT01063556Kidney Failure, Chronic · Japan | 4 | Completed | Eisai | Mar 2010 | 6 |
| NCT01024660Alzheimer Disease · Canada, Peru, Poland and more | Early 1 | Completed | AstraZeneca | Jan 2011 | 155 |
| NCT00959881Alzheimer Disease · United States | 1 | Completed | Pfizer | Nov 2009 | 47 |
| NCT00916383Irritation/Irritant · United States | 2 | Completed | teikoku-pharma-usa-inc | Jun 2009 | 49 |
| NCT00934375Cognitive Dysfunction · United States | 4 | Completed | Eisai | Sep 2007 | 145 |
| NCT01146509Migraine Disorders · United States | 2 | Completed | Eisai | Apr 2004 | 89 |
| NCT00777608Alzheimer Disease | 1 | Completed | Merck | Oct 2009 | 106 |
| NCT00754052Down Syndrome · United States | 3 | Terminated | Eisai | Nov 2008 | 8 |
| NCT00754013Down Syndrome · United States | 3 | Terminated | Eisai | Oct 2008 | 9 |
| NCT00713765Alzheimer Disease · United Kingdom | 1 | Terminated | AstraZeneca | Dec 2008 | 33 |
| NCT00688376Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eisai | May 26, 2009 | 72 |
| NCT00675025Down Syndrome · United States | 2 | Terminated | Eisai | Nov 13, 2008 | 117 |
| NCT00630851Alzheimer Disease · Sweden | 3 | Completed | Pfizer | 249 | |
| NCT00711204Alzheimer Disease · United States | 4 | Withdrawn | Eisai | Jun 2009 | 0 |
| NCT00598650Lewy Body Disease | 2 | Completed | Eisai | Mar 2011 | 160 |
| NCT00571064Mild to Severe Alzheimer's Disease · United States | 4 | Completed | Eisai | Dec 2008 | 97 |
| NCT00570128Down Syndrome · United States | 2 | Completed | Eisai | Sep 5, 2008 | 129 |
| NCT00566501Alzheimer Disease · United States | 3 | Completed | Eisai | Apr 1, 2010 | 915 |
How it is read
Names in the registry
- “Donepezil”, 26 entries
- “Donepezil Hydrochloride”, 14 entries
- “E2020”, 7 entries
- “Donepezil TDS”, 5 entries
- “Donepezil hydrochloride”, 5 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 38 studies
- Down Syndrome, 5 studies
- Lewy Body Disease, 4 studies
- Cognitive Dysfunction, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.